nach oben

International Journal of Clinical Oncology

Erschienen in:

01.04.2013 | Original Article

Clinicopathological significance of hypoxia-inducible factor-1 alpha (HIF-1α) expression in gastric cancer

verfasst von: Taro Isobe, Keishiro Aoyagi, Kikuo Koufuji, Kazuo Shirouzu, Akihiro Kawahara, Tomoki Taira, Masayoshi Kage

Erschienen in: International Journal of Clinical Oncology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Hypoxia is a common feature of rapidly growing solid tumors. Therefore, cellular adaptation to hypoxia and altered glucose metabolism are fundamental to the biology of cancer cells. Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor for more than 60 genes recognized to control the delivery of oxygen and nutrients through the induction of angiogenesis and glycolysis under hypoxic conditions. Therefore, inhibition of the expression of HIF-1α can be expected to be potentially tumor-specific molecular target-based therapy. In this study, we evaluated the significance of HIF-1α expression in relationship to clinicopathological factors, prognosis, vascular endothelial growth factor (VEGF) expression, and microvessel density (MVD).

Methods

Paraffin-embedded tumor specimens from 128 patients who underwent gastrectomy at Kurume University from 2004 to 2005 were used to assess the clinical significance of HIF-1α expression. We used the ABC method to perform an immunohistochemical analysis of the HIF-1α and VEGF expression.

Results

Eighty-four (65.6%) of gastric cancer specimens were positive for HIF-1α expression. Multivariate analysis showed that histology, depth of invasion, VEGF expression, and MVD were significantly associated with HIF-1α expression. On relapse-free and overall survival curves, the HIF-1α-negative group was significantly higher than the HIF-1α-positive group. Moreover, HIF-1α(+)/VEGF(+) patients had the worst prognosis. HIF-1α expression was identified as a significant predictor of relapse-free survival and overall survival by multivariate Cox’s proportional hazard analyses.

Conclusion

Overexpression of HIF-1α was found to be an indicator of poor prognosis for patients with gastric cancer and was significantly correlated with histology, depth of invasion, VEGF, and MVD.

Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2:533–543PubMedCrossRef

Liao D, Johnson RS (2007) Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 26:281–290PubMedCrossRef

Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186PubMedCrossRef

Gatenby RA, Kessler HB, Rosenblum JS et al (1988) Oxygen distribution in squamous cell carcinoma metastasis and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14:531–538CrossRef

Takahashi R, Tanaka S, Hiyama T et al (2003) Hypoxia-inducible factor 1 alpha expression and angiogenesis in gastrointestinal stromal tumor of stomach. Oncol Rep 10:797–802PubMed

Zhong H, Agani F, Baccala AA et al (1998) Increased expression of hypoxia-inducible factor 1 alpha in rat and human prostate cancer. Cancer Res 58:5280–5284PubMed

Chen WT, Huang CJ, Wu MT et al (2005) Hypoxia-inducible factor 1 alpha is associated with risk of aggressive behavior and tumor angiogenesis in gastrointestinal stromal tumor. Jpn J Clin Oncol 35:207–213PubMedCrossRef

Mizokami K, Kakeji Y, Oda S et al (2006) Clinicopathological significance of hypoxia-inducible factor 1 alpha overexpression in gastric carcinomas. J Surg Oncol 94:149–154PubMedCrossRef

Yoshikawa T, Tsuburaya A, Miyagi Y et al (2006) Up-regulation of hypoxia-inducible factor 1 alpha and VEGF mRNAs in peritoneal dissemination of patients with gastric cancer. Anticancer Res 63:3849–3854

10.

Sumiyoshi Y, Kakeji Y, Egashira A et al (2006) Overexpression of hypoxia-inducible factor 1 alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin Cancer Res 12:5112–5117PubMedCrossRef

11.

Stoeltzing O, McCarty MF, Wey JS et al (2004) Role of hypoxia-inducible factor 1 alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst 96:946–956PubMedCrossRef

12.

Fukuda R, Kelly B, Semenza GL (2003) Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E₂ is mediated by hypoxia-inducible factor 1. Cancer Res 63:2330–2334PubMed

13.

Koshikawa N, Iyozumi A, Gassmann M (2003) Constitutive upregulation of hypoxia-inducible factor 1 alpha mRNA occurring in highly metastatic lung carcinoma cells leads to vascular endothelial growth factor overexpression upon hypoxic exposure. Oncogene 22:6717–6724PubMedCrossRef

14.

Semenza GL (2001) Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med 7:345–350PubMedCrossRef

15.

Saramaki OR, Savinainen KJ, Nupponen NN et al (2001) Amplification of hypoxia-inducible factor 1 alpha gene in prostate cancer. Cancer Genet Cytogenet 128:31–34PubMedCrossRef

16.

Ravi R, Mookerjee B, Bhujwalla ZM et al (2000) Regulation of tumor angiogenesis by p53 induced degradation of hypoxia-inducible factor 1α. Genes Dev 14:34–44PubMed

17.

Kung AL, Wang S, Klco JM et al (2000) Suppression of tumor growth through disruption of hypoxia inducible transcription. Nat Med 6:1335–1340PubMedCrossRef

18.

Akakura N, Kobayashi M, Horiuchi I et al (2001) Constitutive expression of hypoxia-inducible factor-1 alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 61:6548–6554PubMed

19.

Dalgard CL, Lu H, Mohyedin A et al (2004) Endogenous 2-oxoacids differentially regulate expression of oxygen sensors. Biochem J 380:419–424PubMedCrossRef

20.

Huang LE, Gu J, Schau M (1998) Regulation of hypoxia-inducible factor 1 alpha is mediated by O₂-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 95:7987–7992PubMedCrossRef

21.

Talks KL, Turley H, Gatter KC et al (2000) The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157:411–421PubMedCrossRef

22.

Chun YS, Kim MS, Park JW (2002) Oxygen-dependent and -independent regulation of HIF-1alpha. J Korean Med Sci 17:581–588PubMed

23.

Shi YH, Fang WG (2004) Hypoxia-inducible factor-1 in tumor angiogenesis. World J Gastroenterol 10:1082–1087PubMed

24.

Stroka DM, Burkhardt T, Desbaillets I et al (2001) HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia. FASEB J 15:2445–2453PubMed

25.

Zagzag D, Zhong H, Scalzitti JM et al (2000) Expression of hypoxia-inducible factor 1 alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer (Phila) 88:2606–2618CrossRef

26.

Theodoropoulos VE, Lazaris A, Sofras F et al (2004) Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 46:200–208PubMedCrossRef

27.

Bos R, Zhong H, Hanrahan CF et al (2001) Levels of hypoxia-inducible factor 1 alpha during breast carcinogenesis. J Natl Cancer Inst 93:309–314PubMedCrossRef

28.

Kuwa T, Kitada Y, Tanaka S et al (2003) Expression of hypoxia-inducible factor 1 alpha is associated with tumor vascularization in human colorectal carcinoma. Int J Cancer 105:176–181CrossRef

29.

Wiesener MS, Munchenhagen PM, Berger I et al (2001) Constitutive activation of hypoxia-inducible factor-1 alpha in clear cell renal carcinomas. Cancer Res 61:5215–5222PubMed

30.

Birner P, Schindl M, Obermair A et al (2001) Expression of hypoxia-inducible factor 1 alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 7:1661–1668PubMed

31.

Buchler P, Reber HA, Buchler M et al (2003) Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas 26:56–64PubMedCrossRef

32.

Japanese Gastric Cancer Association (2010) Japanese classification of gastric carcinoma, 14th edn. Kanehara, Tokyo

33.

Livingston DM, Shivdasani R (2001) Toward mechanism-based cancer care. JAMA 285:588–593PubMedCrossRef

34.

Oskoski R Jr (2007) Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 62:179–213CrossRef

35.

Senger DR, Galli SJ, Dvorak AM et al (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983–985PubMedCrossRef

36.

Dvorak HF, Brown LF, Detmar M et al (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029–1039PubMed

37.

Nagy JA, Masse EM, Herzberg KT et al (1995) Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 55:360–368PubMed

38.

Boocock CA, Charnock-Jones DS, Sharkey AM et al (1995) Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 87:506–516PubMedCrossRef

39.

Aoyagi K, Kouhuji K, Takeda J et al (2005) VEGF significance in peritoneal recurrence from gastric cancer. Gastric Cancer 8:155–163PubMedCrossRef

40.

Imaizumi T, Aoyagi K, Shirouzu K et al (2010) Suppressive effect of bevacizumab on peritoneal dissemination from gastric cancer in a peritoneal metastasis model. Surg Today 40:851–857PubMedCrossRef

41.

Chen C, Pore N, Behrooz A et al (2001) Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 276:9519–9525PubMedCrossRef

42.

Jiang BH, Agani F, Passaniti A et al (1997) V-SRC induces expression of hypoxia-inducible factor 1(HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 57:5328–5335PubMed

43.

Laughner E, Taghavi P, Chiles K et al (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21:3995–4004PubMedCrossRef

44.

Mazure NM, Chen EY, Laderoute KR et al (1997) Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 90:3322–3331PubMed

45.

Aebersold DM, Burri P, Beer KT et al (2001) Expression of hypoxia-inducible factor 1 alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61:2911–2916PubMed

46.

Matuyama T, Nakanishi K, Hayashi T et al (2005) Expression of hypoxia-inducible factor 1α in esophageal squamous cell carcinoma. Cancer Sci 96:176–182CrossRef

47.

Koukourakis MI, Giatromanolaki A, Skarlatos J et al (2001) Hypoxia-inducible factor (HIF-1α and HIF-2α) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 61:1830–1832PubMed

48.

Beasley NJP, Leek R, Alam M et al (2002) Hypoxia-inducible factor HIF-1α and HIF-2α in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 62:2493–2497PubMed

49.

Griffiths EA, Pritchard SA, Valentine HR et al (2007) Hypoxia-inducible factor 1 alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastroesophageal adenocarcinomas. Br J Cancer 96:95–103PubMedCrossRef

50.

Krishnamachary B, Berg-Dixon S, Kelly B et al (2003) Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 63:1138–1143PubMed

51.

Yuri K, Qun L, Daniel Z et al (2009) Hypoxia-regulated delta-like 1 homologue enhances cancer cell stemness and tumorigenicity. Cancer Res 69:9271–9280CrossRef

52.

Wen WM, Alex AA (2009) Novel agents on the horizon for cancer therapy. CA Cancer 59:111–137CrossRef

Titel: Clinicopathological significance of hypoxia-inducible factor-1 alpha (HIF-1α) expression in gastric cancer
verfasst von: Taro Isobe
Keishiro Aoyagi
Kikuo Koufuji
Kazuo Shirouzu
Akihiro Kawahara
Tomoki Taira
Masayoshi Kage
Publikationsdatum: 01.04.2013
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 2/2013
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-012-0378-8

Springer Medizin

Clinicopathological significance of hypoxia-inducible factor-1 alpha (HIF-1α) expression in gastric cancer